July 07, 2009
Creon delayed-release capsules available for exocrine pancreatic insufficiency
The FDA-approved Creon formulation is available in 6,000 lipase units, 12,000 lipase units, and 24,000 lipase units dosage strengths. The previously marketed formulation of Creon will continue to be available for a brief transitional period. However, beginning July 7th, 2009 prescribers and pharmacists should begin writing and filling Creon prescriptions reflecting the new, FDA-approved dosage strengths. Creon will have new trade dress and capsule imprints to distinguish the former capsules from the current FDA-approved formulation.
For more information call (800) 354-0026 or visit www.creon.com.